BMS-641988

Research use only, not for human use.

BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM.

BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM; displays high selectivity over the glucocorticoid and progesterone receptors; displayed 3-7-fold increased antagonist activity of AR transactivation compared with bicalutamide; strongly inhibits androgen-dependent growth of the ventral prostate and seminal vesicles in rats, and is efficacious in CWR-22-BMSLD1 tumors initially refractory to treatment with bicalutamide.Prostate Cancer Phase 1 Clinical

BMS 641988;BMS641988

Endocrinology/Hormones

Androgen Receptor (AR)

Androgen Receptor (AR)

Cancer

Prostate Cancer

573738-99-5

471.45

C20H20F3N3O5S

>98% (HPLC)

——

CCS(=O)(N[C@H](C[C@]1(C)[C@@]23[H])[C@@](O1)(C)[C@]3([H])C(N(C4=CC=C(C#N)C(C(F)(F)F)=C4)C2=O)=O)=O

N-((3aR,4R,5R,7R,7aS)-2-(4-cyano-3-(trifluoromethyl)phenyl)-4,7-dimethyl-1,3-dioxooctahydro-1H-4,7-epoxyisoindol-5-yl)ethanesulfonamide

(-20℃)

With Ice Pack

≥ 2 years